Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers
Autore:
Pan, WJ; Gustavson, LE; Achari, R; Rieser, MJ; Ye, X; Gutterman, C; Wallin, BA;
Indirizzi:
Abbott Labs, Dept Clin Pharmacokinet & Toxicokinet, Dept 4PK, Abbott Pk, IL 60064 USA Abbott Labs Abbott Pk IL USA 60064 net, Dept 4PK, Abbott Pk, IL 60064 USA Abbott Labs, Dept Clin Pharmacol, Abbott Pk, IL 60064 USA Abbott Labs Abbott Pk IL USA 60064 lin Pharmacol, Abbott Pk, IL 60064 USA Abbott Labs, Dept Stat, Abbott Pk, IL 60064 USA Abbott Labs Abbott Pk IL USA 60064 bs, Dept Stat, Abbott Pk, IL 60064 USA Abbott Labs, Cardiovasc Diabet Venture, Abbott Pk, IL 60064 USA Abbott Labs Abbott Pk IL USA 60064 iabet Venture, Abbott Pk, IL 60064 USA
Titolo Testata:
JOURNAL OF CLINICAL PHARMACOLOGY
fascicolo: 3, volume: 40, anno: 2000,
pagine: 316 - 323
SICI:
0091-2700(200003)40:3<316:LOACSP>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
HMG-COA REDUCTASE; COMBINED HYPERLIPIDEMIA; MICRONIZED FENOFIBRATE; INHIBITORS; PHARMACODYNAMICS; CHOLESTEROL; HYPERCHOLESTEROLEMIA; DISPOSITION; LOVASTATIN; METABOLISM;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Pan, WJ Abbott Labs, Dept Clin Pharmacokinet & Toxicokinet, Dept 4PK, BldgAP13A-3,100 Abbott Pk Rd, Abbott Pk, IL 60064 USA Abbott Labs Bldg AP13A-3,100 Abbott Pk Rd Abbott Pk IL USA 60064 A
Citazione:
W.J. Pan et al., "Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers", J CLIN PHAR, 40(3), 2000, pp. 316-323

Abstract

This study was conducted to evaluate the potential pharmacokinetic interaction between fenofibrate and pravastatin. A total of 23 healthy adult volunteers received single-dose 201 mg fenofibrate alone, 201 mg fenofibrate + 40 mg pravastatin, and 40 mg pravastatin alone in a three-period crossover experiment. Plasma samples were collected at predetermined times and were analyzed with validated methods for the quanfitation of fenofibric acid, pravastatin, and 3 alpha-hydroxy-iso-pravastatin (3 alpha-iso-PV). Pharmacokinetic parameters of these three compounds were calculated using noncompartmental methods and compared by analyses of variance and bioavailability assessments. Concomitant administration of fenofibrate and pravastatin did not affect the pharmacokinetics of either fenofibric acid or pravastatin. However, the AUC(0-infinity), and C-max of 3 alpha-iso-PV were increased by 26% and 29% respectively. The moderate increase in the formation of this pravastatin metabolite should not mise any clinical concerns due to its much lower pharmacological potency compared to pravastatin and lack of toxicity. (C)2000 the American College of Clinical Pharmacology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/07/20 alle ore 07:01:30